These dividend stocks are great picks as the fall season gets underway.Cousin Eddie in the movie Christmas Vacation thought a one-year membership in the Jelly of the Month club was "the gift that keeps on giving the whole year." But for investors, there's an even better gift that keeps on giving: dividend stocks. Three Motley Fool contributors believe they have identified magnificent dividend stocks to buy in October -- and all of them are drugmakers. Here's why they picked AbbVie (ABBV -0.59%), Amgen (AMGN ...

Declining earnings haven't scared billionaire investors away from this stock.Dividend stocks aren't just for folks who want to build up a stream of passive income. Billionaire investors who don't need any more income to retire comfortably regularly invest in businesses that pay dividends because they tend to outperform their non-dividend-paying cousins over time.Non-dividend-paying stocks in the S&P 500 index produced an average annual return of just 4.27% during the 50 years between 1973 and 2023. Dividend ...

These companies can lend growth and dividend returns to a long-term investor's portfolio.Dividend stocks can offer a fantastic way to magnify your returns with time and offer additional cash to reinvest or keep on the sidelines as savings. Not all dividend stocks are alike, and it's important to consider various elements of the underlying business to make sure the company aligns with your overall portfolio objectives.The best dividend stocks have a history of paying and raising dividends, and strong busines ...

AbbVie (ABBV) announced in a regulatory filing that it is lowering its previously issued guidance for 2024 adjusted earnings per share by 4 cents per share to account for acquired in-process research and development (IPR&D) expenses incurred for acquisitions and collaborations in the third quarter. AbbVie is set to report its third-quarter results on Oct. 30.The adjusted earnings guidance for 2024 was lowered from $10.71-$10.91 per share to $10.67 - $10.87 to account for acquisition costs of $82 million on ...

Group 1 - AbbVie, Inc. announced the acquisition of Cerevel Therapeutics for $8.7 billion, enhancing its neuroscience pipeline with promising candidates like Emraclidine and Tavapadon [1] - The acquisition was completed in December 2023, indicating AbbVie's strategic focus on expanding its capabilities in neuroscience [1] Group 2 - The company has a strong background in life sciences, with over 20 years of experience in research and development of novel Cell & Gene Therapies [1] - AbbVie aims to leverage its expertise in life sciences to assess the potential of new treatments and their ability to drive shareholder returns [1]

Core Insights - AbbVie presents a strong investment opportunity for long-term growth, particularly in its neuroscience sector [1] Company Analysis - The company has been closely monitored for its recent developments, indicating a positive outlook for investors [1] - AbbVie operates in dynamic industries such as healthcare, which is highlighted as a focus area for investment [1]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Group 1 - The article discusses the potential for investors to identify undervalued stocks that are mispriced by the market as the fourth quarter approaches [1] - It highlights the services offered by the investing group Out Fox The Street, which includes stock picks, model portfolios, and real-time alerts to assist investors in uncovering potential multibaggers while managing portfolio risk [1] Group 2 - The article emphasizes the importance of conducting personal research or consulting a financial advisor before making investment decisions [2] - It notes that past performance is not indicative of future results, and no specific investment recommendations are provided [2]

Group 1 - The article emphasizes the importance of conducting personal in-depth research before making investment decisions due to the inherent risks involved [2] - It highlights that past performance is not indicative of future results, suggesting caution for investors [2] - The analysis is presented as informational and does not constitute professional investment advice, indicating that readers should consider their own financial situations [2] Group 2 - The article mentions that the analysts contributing to the platform may not be licensed or certified, which could affect the reliability of the information provided [2] - It clarifies that there are no existing stock or derivative positions in the companies mentioned, which may suggest an unbiased perspective [1] - The disclosure indicates that the opinions expressed are personal and not influenced by any business relationships with the companies discussed [1]

Core Insights - Allergan Aesthetics has announced the national availability of JUVÉDERM® VOLUMA® XC for treating moderate to severe temple hollowing, following its FDA approval in March 2024, making it the first and only hyaluronic acid filler approved for this indication [1][2][4] Product Launch and Training - The company has implemented a robust training protocol for providers to ensure they are well-versed in the science of injecting the temple area, emphasizing the importance of comprehensive training for all Allergan Aesthetics products [2][4] - JUVÉDERM® VOLUMA® XC is part of the JUVÉDERM® Collection, which includes six specifically formulated hyaluronic acid fillers designed to meet various aesthetic goals [2][4] Patient Satisfaction and Efficacy - Approximately 90% of patients reported satisfaction with the natural look and feel of their temples three months post-treatment, and over 85% noted overall aesthetic improvement one month after treatment, with results lasting up to 13 months [2][4] - A high satisfaction rate of 98% of patients treated in the temple area would recommend the treatment to a friend, indicating strong consumer confidence in the product [2][4] Safety and Approval - JUVÉDERM® VOLUMA® XC has an established safety profile and is approved for adults of all Fitzpatrick skin types over 21 years of age, ensuring broad applicability [2][4] - The product is designed to create a balanced and youthful appearance, making it an ideal choice for patients seeking subtle, natural-looking results [2][4] Loyalty Program and Consumer Education - Patients interested in JUVÉDERM® VOLUMA® XC for temple hollowing are encouraged to enroll in Allē, Allergan Aesthetics' loyalty rewards program, which serves over seven million members across approximately 30,000 practices [3][4] - Allē aims to educate consumers about aesthetic treatments and simplify office operations for practices, enhancing the overall treatment journey for patients [3][4]